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Abstract
Introduction: For both patients and the outpatient clinic the frequent follow-up visits after a resection of colorectal cancer
(CRC) are time consuming and due to large patient numbers expensive. Therefore it is important to develop an effective
non-invasive test for the detection of colorectal liver metastasis (CRLM) which could be used outside the hospital. The urine
proteome is known to provide detailed information for monitoring changes in the physiology of humans. Urine collection is
non-invasive and urine naturally occurring peptides (NOPs) have the advantage of being easily accessible without labour-
intensive sample preparation. These advantages make it potentially useful for a quick and reliable application in clinical
settings. In this study, we will focus on the identification and validation of urine NOPs to discriminate patients with CRLM
from healthy controls.
Materials and Methods: Urine samples were collected from 24 patients with CRLM and 25 healthy controls. In the first part
of the study, samples were measured with a nano liquid chromatography (LC) system (Thermo Fisher Scientific, Germaring,
Germany) coupled on-line to a hybrid linear ion trap/Orbitrap mass spectrometer (LTQ-Orbitrap-XL, Thermo Fisher Scientific,
Bremen, Germany). A discovery set was used to construct the model and consecutively the validation set, being
independent from the discovery set, to check the acquired model. From the peptides which were selected, multiple reaction
monitoring (MRM’s) were developed on a UPLC-MS/MS system.
Results: Seven peptides were selected and applied in a discriminant analysis a sensitivity of 84.6% and a specificity of 92.3%
were established (Canonical correlation:0.797, Eigenvalue:1.744, F:4.49, p:0.005). The peptides AGPP(-OH)GEAGKP(-
OH)GEQGVP(-OH)GDLGA P(-OH)GP and KGNSGEP(-OH)GAPGSKGDTGAKGEP(-OH)GPVG were selected for further quantita-
tive analysis which showed a sensitivity of 88% and a specificity of 88%.
Conclusion: Urine proteomic analysis revealed two very promising peptides, both part from collagen type 1, AGPP(-
OH)GEAGKP(-OH)GEQGVP(-OH)GDLGAP(-OH)GP and KGNSGEP(-OH)GAPGSKGDTGAKGEP(-OH)GPVG which could detect
CRLM in a non-invasive manner.
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Introduction
Colorectal cancer (CRC) is the most common gastrointestinal
malignancy worldwide and the 3rd leading cause of cancer-related
deaths in the western world. More than one-third of the patients
develop colorectal liver metastases (CRLM) during the course of
the disease, which are responsible for at least two-thirds of the
deaths [1].
For the follow-up after CRC, blood level Carcinoembryonic
antigen (CEA) is used to detect CRLM with a wide spread of
sensitivity ranging from 58 to 89 percent [2,3]. Because of this
suboptimal sensitivity, liver imaging with ultrasonography and
computer tomography are performed on a routine base. For both
patients and the outpatient clinic the frequent follow-up visits are
time consuming and due to large patient numbers expensive.
Therefore it is important to develop an effective non-invasive test
for the detection of CRLM which could be used outside the
hospital.
Proteomic patterns in body fluids present new opportunities for
the development of novel, highly sensitive diagnostic tools for
detection of cancer [4,5]. The urine proteome is known to provide
detailed information for monitoring changes in the physiology of
humans [5,6]. Urine collection is non-invasive and urine naturally
occurring peptides (NOPs) have the advantage of being easily
accessible without labour-intensive sample preparation [7]. These
advantages make it potentially useful for a quick and reliable
application in clinical settings. To prove the concept it is possible
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to differentiate between different liver tumors (CRLM, Hepato-
cellular Carcinoma (HCC), Hepatocellular Adenoma) and not
only measure peptides involved in the process of general tumor
growth in the liver, we conducted a pilot-study. In the current
study we demonstrated we could discriminate between these liver
tumors with the use of peptides found in urine (unpublished work,
poster presentation ESMO 2010). In this study, we will focus on
the identification and validation of urine NOPs to discriminate
patients with CRLM from healthy controls.
Materials and Methods
Ethics Statement
The use of patient materials was approved by the medical
ethical committee of Erasmus Univercity Medical Center and
written informed consent was obtained for all patients.
Patient selection
We selected patients with Colorectal Liver metastasis (CRLM)
and healthy kidney donors as controls. Inclusion criteria were;
female gender, age above 18 years and written informed consent.
The patients with CRLM underwent liver resection and their
diagnoses were confirmed by the pathologist afterwards. Patients
and controls were excluded if they were diagnosed with other
malignancies or received prior chemotherapy.
A discovery set was formed of 23 patients that contained 11
patients with CRLM and 12 controls. In addition a validation set
was formed with 26 patients, 13 with CRLM, and 13 controls.
Sample collection
From patients with CRLM, 100 ml urine was collected
(midstream morning urine of sober patients). Fifty ml of urine
was sent to the chemical laboratory at room temperature for
determination of standard parameters (e.g. creatinine, total urine
protein). Aliquots of 10 ml were made from the remaining 50 ml
urine and stored within 4 hours from sample withdrawal at
280uC.
Sample preparation
Preparation of samples for proteomic analysis was performed as
described previously [8] with some minor modifications. In brief,
urine samples were thawed at room temperature and placed in a
water bath for 309at 30uC with regular mixing to dissolve the
precipitate. At room temperature, 1.4 ml urine was centrifuged to
remove remaining precipitate for 59 at 2000 g. A volume of 1.2 ml
of urine was diluted with 0.6 ml 3 M urea, 15 mM NH4OH,
0.03% (w/v) SDS solution. From this mixture, 1.5 ml high
molecular weight components were discarded using Centrisart
ultracentrifugation columns (Sartorius, Goettingen, Germany)
with a molecular cut-off limit of 20 kDa at a centrifugal force of
2500 g for 109. From this filtered sample 1.2 ml was applied to a
PD-10 desalting column (GE Healthcare) equilibrated with 25 ml
0.01% NH4OH and allowed to completely enter the filter bed. To
improve the yield of natural occurring peptides (NOPs), 1.3 ml of
equilibration buffer was applied to the filter bed as a first step and
allowed to wash out by gravity flow. Subsequently, 2 ml of
equilibration buffer was applied to the PD-10 column, the flow-
through was collected, lyophilized, and stored at +4uC until
further use. Prior to analysis by the nano-liquid chromatography/
mass spectrometry (LC-MS), samples were suspended in 50 ml of
HPLC-grade H2O. For estimating the NOP content with the BCA
assay (Pierce) 4 mL of sample was used. With the use of this
information the sample was diluted to 0.8 mg peptide/ml to 0.1%
trifluoroacetic acid/water for normalization.
Qualitative Mass spectrometry analysis (Orbitrap)
In the first part of the study, samples were measured with a
nano liquid chromatography (LC) system (Thermo Fisher Scien-
tific, Germaring, Germany) coupled on-line to a hybrid linear ion
trap/Orbitrap mass spectrometer (LTQ-Orbitrap-XL, Thermo
Fisher Scientific, Bremen, Germany). Samples were loaded onto a
trap column (PepMap C18, 300 mm ID 5 mm length, 5 mm
particle size, 100 A˚ pore size; Thermo Fisher Scientific), washed
and desalted for 10 minutes using 0.1% trifluoroacetic acid (TFA)
(in water) as loading solvent. Next, the trap column was switched
inline with the analytical column (PepMap C18, 75 mm ID
6250 mm, 3 mm particle and 100 A˚ pore size; Thermo Fisher
Scientific) and peptides were eluted with the following binary
Table 1. The three transitions which have been developed for each peptide and the optimized collision energies.
Peptide Parent mass (m/z) Fragment (m/z) Collision energy (V)
AGP P(-OH)GEAGK* P(-OH)GEQGV P(-OH)GDLGA P(-OH)GP 1088.51 527.28 37
812.38 33
1364.64 33
1092.52 527.28 37
812.38 33
1372.66 33
K*GNSGEP(-OH)GAPGSK*GDTGAK*GEP(-OH)GPVG 786.04 442.23 29
814.37 29
957.94 25
794.05 442.23 29
822.38 29
969.96 25
For each stable isotope labeled amino acid an extra mass of 8 Da is included.
m/z (mass-to-charge ratio); V (Voltage).
doi:10.1371/journal.pone.0070918.t001
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gradient: starting with 100% solvent A, then from 0% to 25%
solvent B in 60 min and from 25% to 50% solvent B in 30 min,
where solvent A consisted of 2% acetonitrile and 0.1% formic acid
(rest water), and solvent B consisted of 80% acetonitrile and 0.08%
formic acid (rest water). All LC solvents were purchased at
Biosolve, Valkenswaard, the Netherlands. Column flow rate was
set at 300 nL/min. For electro-spray ionization (ESI), nano ESI
emitters (New Objective, Woburn, MA, USA) were used and a
spray voltage of 1.5 kV was applied. For Mass Spectrometry (MS)
detection, a data-dependent acquisition method was used: high-
resolution survey scan from 400–1800 Th. was detected in the
Orbitrap (target of automatic gain control = 10 E6, resolution
= 30,000 at 400 m/z, lock mass set to 445.120025 Th (protonated
(Si(CH3)2O))6) [9]). On the basis of this full scan the five most
intensive ions were consecutively isolated (AGC target set to 104
ions) and fragmented by collisional activated dissociation (applying
35% normalized collision energy) and detected in the ion trap.
Precursor masses within a tolerance range of +/2 5 ppm that
were selected once for MS/MS were excluded for MS/MS
fragmentation for 3 minutes or until the precursor intensity fell
below an S/N of 1.5 for more than five scans (early expiration).
Orbitrap full scan spectra and ion trap MS/MS fragmentation
spectra were acquired partially simultaneously.
Data analysis
The MS/MS data from the raw data files of each sample were
converted into mgf files using Extract-MSN (part of XCalibur
version 2.0.7, Thermo Fisher Scientific Inc.) and used to perform
database searches using Mascot (version 2.2.06; Matrix Science
Inc., London, UK) against the human subset of the Uniprot-
Figure 1. ROC-curves of the selected peptides AGPP(-OH)GEAGKP(-OH)GEQGVP(-OH)GDLGAP(-OH)GP and P(-OH)GNSGEP(-
OH)GAP(-OH)GSKGDTGAKGEP(-OH)GPVG.
doi:10.1371/journal.pone.0070918.g001
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Swissprot database (version 2011–3, human taxonomy, 20,287
entries). For database searches the following parameters were used:
oxidation as a variable modification of methionine, hydroxylation
as a variable modification of proline and lysine, maximal missed
cleavage of 0, and ‘‘none’’ was selected as enzyme. A peptide mass
tolerance of 10 ppm and a MS/MS mass tolerance of 0.5 Da were
accepted. An ion score of 25 was used as a cut-off value.
Subsequently, the raw data files were loaded into the software
package Progenesis LCMS (Version 2.5; Nonlineair Dynamics
Ltd, New Castle, UK) and aligned for retention time., Only
features with a charge state of +2 to+8 were included for further
analyses. Next, the results of the Mascot database search were
imported into Progenesis, and an export file was created in which
for each individual sample the abundances of the detected features
were displayed. Abundance levels of masses identified multiple
times in one sample were summed into single abundance values
prior to statistical analysis. To eliminate sporadic findings,
identified masses not present in at least 3 samples of one group
were subsequently excluded from further analysis.
Statistical analysis
Statistical analyses on the patient characteristics were conducted
in the Statistical Package for the Social Sciences (SPSS) version
20.0 (IBM Corp. Released 2011. IBM SPSS Statistics for
Windows, Version 20.0. Armonk, NY: IBM Corp). Categorical
variables are presented as number (percentage). Continuous
variables are presented as median (range), Categorical variables
were compared, after testing for normality, with the Chi-square
test; continuous variables were compared with the Independent T-
test test. A p-value ,0.05 (two-sided) was considered significant.
Table 2. Basic patient characteristics.
Variable CRLM (n=24) Healthy kidney donors (n=25) p- value
Age1,3 64 (43–81) 57 (34–75) 0.01
BMI1,3 23.6 (18–36) 27.3 (20–35) 0.04
No. of lesions1 2 (1–7) { - -
Size largest lesion (cm)1 3 (1–10) { - -
Serum creatinine .115 mM2,4 1{ (4%) 0 0.29
Urine protein .0.14 g/L2,4 3 (12.5%) 0 0.07
{1 missing
CRLM, Colorectal Liver Metastasis; BMI, Body Mass Index.
1Data are presented as median with the range between brackets.
2Data are presented as numbers with the percentage between brackets.
Data were analyzed using a 3Independent T-test or the 4Chi-squared test.
doi:10.1371/journal.pone.0070918.t002
Table 3. Sequences of the 17 Peptides used for the first model in the discovery set.
Mass (Da) Sequence
Accesion
code
2204.995 ADGQPGAKGEP(2OH)GDAGAKGDAGPP(2OH)GP COL1A1
2175.011 AGPP(2OH)GEAGKP(2OH)GEQGVP(2OH)GDLGAP(2OH)GP COL1A1
1927.909 DP(2OH)GETGEQGDRGIP(2OH)GHRG COL1A1
1778.855 GAAGEP(2OH)GKAGERGVP(2OH)GPP(2OH)GA COL1A1
2628.235 GLPGP(2OH)AGP(2OH)P(2OH)GEAGKP(2OH)GEQGVP(2OH)GDLGAP(2OH)GP COL1A1
2561.128 GPP(2OH)GADGQP(2OH)GAP(2OH)GEP(2OH)GDAGAKGDAGP(2OH)PGP COL1A1
2632.164 GPP(2OH)GADGQP(2OH)GAP(2OH)GEP(2OH)GDAGAKGDAGP(2OH)PGPA COL1A1
2786.247 GPP(2OH)GADGQP(2OH)GAKGEP(2OH)GDAGAP(2OH)GDAGP(2OH)PGPAGP COL1A1
2516.165 GPP(2OH)GKNGDDGEAGKP(2OH)GRP(2OH)GERGP(2OH)PGP COL1A1
1734.781 GPP(2OH)GPP(2OH)GKNGDDGEAGKPG COL1A1
1408.664 GPPGP(2OH)P(2OH)GP(2OH)PGPPGPPS COL1A1
2371.086 P(2OH)GNSGEP(2OH)GAP(2OH)GSKGDTGAKGEP(2OH)GPVG COL1A1
2355.098 KGNSGEP(2OH)GAP(2OH)GSKGDTGAKGEP(2OH)GPVG COL1A1
1522.732 KP(2OH)GEQGVP(2OH)GDLGAP(2OH)GP COL1A1
2989.483 NVGAP(2OH)GAKGARGSAGP(2OH)P(2OH)GATGFP(2OH)GAAGRVGPPGP(2OH) COL1A1
2973.485 NVGAPGAP(2OH)GARGSAGPP(2OH)GATGFP(2OH)GAAGRVGP(2OH)PGP COL1A1
2670.203 ERGEAGIP(2OH)GVP(2OH)GAP(2OH)GEDGKDGSP(2OH)GEP(2OH)GA COL3A1
The amino acids which are underscored are hydroxylated. The two peptides which are written in bold are the finally selected peptides. (COL1A1 Collagen, type I, alpha
1).
doi:10.1371/journal.pone.0070918.t003
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Statistical analysis of the observations as obtained from mass
spectrometry was performed using STATA (version 10, Stata-
Corp, Texas, US). After testing for normality, using Shapiro-
Wilks, univariate comparison between individuals from the groups
was performed using Mann-Whitney U-test (parameter free) or
unpaired t-test (parametric). This yielded many features (in raw
abundance format) with significant outcome between the evalu-
ated combinations. Subsequently, the identified features were
analyzed using stepwise regression to construct a model containing
a combination of those features with the highest sensitivity and
specificity to distinguish the respective groups. This was done in
combination with canonical linear discriminant analysis [10] to
detect the various sensitivity and specificity details when the
various models are applied.
Moreover background evaluation was also performed in which
models were applied with at random features and outcome to
compare the acquired sensitivity and specificity with those as
obtained after statistical analysis.
The discovery set was used to construct the model, consecu-
tively the validation set, being independent from the discovery set,
to check the acquired model.
Throughout the study, applying two-sided testing, a significance
level of 0.01 was considered to be statistically relevant.
The discovery set was subjected to a univariate analysis in order
to identify masses significantly different (p,0.01) between CRLM
patients and healthy controls that ought to be present in both
discovery and validation. From the peptides with p-values ,0.01 a
best fit model was made in the discovery set and subsequently
tested in the validation set to determine sensitivity and specificity.
Quantitative mass spectrometry analysis (SRM)
For the peptides selected based on the statistical analysis heavy
labeled stable isotopes were ordered (Pepscan, Lelystad, The
Netherlands). A selective reaction monitoring (SRM) method for
the selected peptides was developed and optimized on a UPLC
which was online connected to a Xevo TQS mass spectrometer
(Waters, Milford Massachusetts, USA).
The sample was trapped on a Symmetry C18 nanoACQUITY
column (5 mm6180 mm 20 mm) (Waters, Milford Massachusetts,
USA) for 5 min and washed by a solution of 99% A and 1% B,
solvent A 0.1% formic acid in water and solvent B is 0.1% formic
acid in acetonitrile, with a flow of 8.00 ml/min. Followed by
separation on an BEH 300 C18 column (1,7 mm * 75 mm *
200 mm) (7 mm675 mm615 cm) with a flow of 0.3 ml/min and a
gradient starting with 98.5% A lowered in 30 min to 60%. In
0.10 min it was further decreased to 20% A and kept constant for
5 min following by an increase in 0.10 min, back to 98.5% for
20 min. Ions were produced by a Z-spray nanoflow source under
atmospheric pressure using a capillary voltage of 3.00 kV, cone
voltage of 50 V and a source offset of 50 V. The source
temperature was maintained at 70uC. For every peptide 3
transitions were chosen differing in collision energy (table 1).
Fragmentation is induced by collision dissociation with argon gas
which is inserted with a flow rate of 0.15 ml/min. For the selection
of the peptides for the final quantitative assay the following
parameters were taken into account: No interference in used SRM
transitions, co-elution of the peptide and internal standard (IS),
linearity of response in measured concentration range, symmetry
of peak shape and a signal intensity of at least 10 times the average
observed background.
Skyline
The following parameters were taken into account for the
selection of the peptides that were used for the SRM assay: no
interference in used SRM transition, co-elution of the peptide and
its internal standard (IS), linearity of response in measured
concentration range and the peak intensity should be at least 10
times above the background level. The peak analysis was done
with Skyline v1.3.0.3871 (MacCoss Lab, University of Washing-
ton, WA, United States of America). The results exported from
Skyline were further analyzed with Microsoft Excel2007 (Red-
mond, WA, United States of America) and GraphPad Prism v5.00
(GraphPad Software, San Diego California USA) A ROC-curve
was plotted by GraphPad Prism v5.00 (GraphPad Software, San
Diego California USA) (figure 1). The cut-off value was chosen
whereby both sensitivity and specificity were as high as possible.
Results
Patient characteristics and clinical chemistry data of the urines
are presented in Table 2. A significant difference in age (p=0.01)
and Body Mass Index (BMI) (p=0.04) is observed. Kidney
function and urine protein were comparable between both groups.
Qualitative Mass spectrometry analysis (Orbitrap)
Of the 28830 and 57276 masses detected in the discovery and
validation set, respectively, 2426 (8.6%) and 3424 (5.8%) unique
peptide sequences were identified. These naturally occurring
peptides belong to 189 and 445 proteins, respectively. Of the
unique peptides identified 1386 (55%) derived from 26 different
collagen proteins in the discovery set and 1303 (39%) from 34 in
the validation set. Of all identified masses 80% of the abundant
intensities is associated with collagen peptides. It occurred that
same peptides were sequenced with one or more hydroxylated
proline or lysine residues. Of all identified collagen peptides, 1702
peptides had 2 or more hydroxylations on either lysine or proline
residues with a maximum of 11. These modified peptides are
considered as unique peptides.
Statistical analysis and regression modeling
Univariate analysis of the discovery set revealed 40 collagen
peptides that were significantly different (p,0.01) between the
healthy individuals and patients with CRLM.
A Multivariate analysis, using stepwise regression was applied in
the discovery set to construct a relevant model using all identified
peptides, showing significance between healthy individuals and
CRLM patients. To obtain a 100% sensitivity and 100%
specificity a 17-collagen peptides model was identified (Canonical
correlation:0.9911, Eigenvalue:55.64, F:16.37, p:0.003) (Table 3).
Analysis of the samples from the validation set returned 58545
masses of which 3442 unique peptides could be identified. Out of
these 3442 peptides, 1304 belonged to 34 different collagens.
Within the validation set, of the original 40 peptides identified in
the discovery set as having a significant difference in raw
abundance between both groups, 7 peptides could be identified.
It was decided to use all 7 peptides to model the outcome based on
the results in the validation set. When these 7 peptides were
applied in a discriminant analysis a sensitivity of 84.6% and a
specificity of 92.3% were established (Canonical correlation:0.797,
Eigenvalue:1.744, F:4.49, p:0.005).
The peptides AGPP(-OH)GEAGK P(-OH)GEQGV P(-
OH)GDLGA P(-OH)GP and KGNSGE P(-OH)GAPGSKGDT-
GAKGE P(-OH)GPVG were selected for further quantitative
mass spectrometry analysis by selective reaction monitoring (SRM)
based on a thorough evaluation on the criteria described in the
materials and method section. The quantitative analysis resulted in
a sensitivity of 88% and specificity of 89% (Figure 1).
Urine to Detect Colorectal Liver Metastases
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These two peptides have been retested in the Orbitrap data
showing a sensitivity and specificity of 72.7% and 100% in the
discovery set and 69.2% and 84.6% in the validation set.
Discussion
Patients
For this study healthy kidney donors have been selected as a
control group. These controls were selected because living kidney
donors are examined intensively to exclude any disease. Because
this specific control group was chosen, which were not matched
with our CRLM-patients, a difference in patient characteristics in
BMI (p= 0.04) and age (p = 0.01) was found. Only women were
selected because the first pilotstudy we have performed included
different solid liver tumors including HCA, a benign liver tumor
which occurs very rarely in men [11].
In this study, a collagen profile has been discovered and
validated in patients who were diagnosed with colorectal liver
metastasis at the time of sampling. To identify the prognostic value
of our profile, we will continue sampling during the regular follow-
up in patients who underwent surgery because of CRC. Thereby
patient variation presumably can be diminished and an even
better sensitivity and specificity can be expected. The short coming
of this study is the small number of patients. However we believe
we describe a very innovative concept for the detection of
colorectal liver metastasis. Furthermore the detection of different
amounts of hydroxylated collagen type 1 may proof to be very
valuable for clinical use and, in addition, it could contribute to the
understanding of the liver seeding and homing of colorectal
metastasis. Larger experiments need to be performed to demon-
strate the efficacy of this approach.
Peptide selection
In this study, only two stable isotope labelled peptides were
technically suitable in our final analysis (table 1).Mischak et al.
already showed data generated by different proteomics technol-
ogies are not always comparable [12]. Although the result could
possibly be improved by taking more significant different peptides,
this study already shows the new possibilities to use urine
proteomic analysis to detect CRLM.
Collagen
The two peptides identified in this study are part of collagen
type 1. Collagens are macromolecular molecules which are
eliminated due to secretion by the kidney. Type I collagen is the
most abundant in stroma which is composed of the the
extracellular matrix (ECM). In the adult liver the ECM is mostly
composed of collagen type 1 and fibronectin [13,14,15,16]. The
structure of the ECM is not static, it remodels constantly as a
consequence of development and disease [17]. This remodelling is
a result of multiple processes that vary according to the initiating
stimulus. The protein components of the ECM are cleaved by
metalloproteinases (MMPs) and they seem to play a dominant role
in this process of remodelling [18]. The remodelling of the ECM is
an essential event before invasion of neoplastic cells into the
stromal tissue and could explain our findings in the urine of
patients with CRLM. The different expressions of type 1 collagen
were also described in the stromal composition of tissue samples
from CRC and CRLM [19]. The combination of these results
provides evidence that type 1 collagen has a role in CRLM.
However further research is needed to support these findings.
Previously our research group identified tumour specific collagen-
like peptides which are located in the blood vessels of brain
tumours. These proteins are expressed in tumour blood vessels,
but not in blood vessels of healthy brain tissue [20].
Hydroxylation
Hydroxylation of peptides provides further stabilization or,
depending on the location of the hydroxylation, the opposite,
namely instability. Normally the hydroxylation in collagen
sequences happens at the terminal residue in Gly–Pro–Pro repeats
[21]. The final classifier existed of two hydroxylated collagen
peptides with a sensitivity of 88%, a specificity of 88%. We
hypothesize that in the liver the post-translational modification
related to hydroxylation in collagen is altered due to the cancer
cell invasion.
Although this study is based on relatively small numbers, urine
proteomic analysis revealed two very promising peptides AGPP(-
OH)GEAGK P(-OH)GEQGV P(-OH)GDLGA P(-OH)GP and
KGNSGE P(-OH)GAPGSKGDTGAKGE P(-OH)GPVG, which
are both part of collagen 1, to detect CRLM in a non-invasive
manner.
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